These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33994017)

  • 41. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
    Johnson BE; Rabin MS
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy.
    Bogart JA; Aronowitz JN
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5004s-5010s. PubMed ID: 16000604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A systematic overview of chemotherapy effects in non-small cell lung cancer.
    Sörenson S; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
    Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
    J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery.
    Thomas DC; Arnold BN; Rosen JE; Salazar MC; Blasberg JD; Detterbeck FC; Boffa DJ; Kim AW
    Lung Cancer; 2017 Jan; 103():75-81. PubMed ID: 28024700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).
    Lee SW; Choi EK; Chung WK; Shin KH; Ahn SD; Kim JH; Kim SW; Suh C; Lee JS; Kim WS; Kim DS; Kim DK; Park SI; Sohn KH
    Lung Cancer; 2002 Jul; 37(1):65-71. PubMed ID: 12057869
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
    Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
    Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Consensus conference on medical treatment of non-small cell lung cancer: adjuvant treatment.
    Tonato M
    Lung Cancer; 2002 Dec; 38 Suppl 3():S37-42. PubMed ID: 12468143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
    Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
    Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
    Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis.
    Kou P; Wang H; Lin J; Zhang Y; Yu J
    Future Oncol; 2018 Oct; 14(23):2371-2381. PubMed ID: 29807451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer.
    Sher DJ; Fidler MJ; Liptay MJ; Koshy M
    Lung Cancer; 2015 Jun; 88(3):267-74. PubMed ID: 25862147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer].
    Noël G; Mazeron JJ
    Cancer Radiother; 2001 Apr; 5(2):195-6. PubMed ID: 11355584
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC).
    Men Y; Luo Y; Zhai Y; Liang J; Feng Q; Chen D; Xiao Z; Zhou Z; Hui Z; Wang L
    Oncotarget; 2017 Jul; 8(30):48922-48929. PubMed ID: 28430661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
    Duan H; Liang L; Xie S; Wang C
    BMC Cancer; 2020 Aug; 20(1):809. PubMed ID: 32847544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
    Onishi H; Kuriyama K; Yamaguchi M; Komiyama T; Tanaka S; Araki T; Nishikawa K; Ishihara H
    Lung Cancer; 2003 Apr; 40(1):79-84. PubMed ID: 12660011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.